TABLE 4.
Comparison of Myeloid Cell Nuclear Differentiation Antigen Expression With the Previous Studies
| n/N (%) | ||||
|---|---|---|---|---|
| Type of lymphoma | Kanellis et al6 | Metcalf and colleagues9,10 | Wang and colleagues10,13 | This study |
| NMZL | 43/57 (75.0) | 16/24 (66.7) | 12/22 (54.0) | 34/50 (68.0) |
| EMZL | 19/20 (95.0) | 27/44 (61.4) | 21/31 (68.0) | 79/94 (84.0) |
| SMZL | 20/20 (100.0) | 5/21 (23.8) | 18/26 (69.0) | 7/10 (70.0) |
| FL | 9/184 (5.0) | 6/110 (5.5) | 3/14 (21.0) | 2/77 (2.6) |
| MCL | 61/74 (82.0) | 9/140 (6.4) | 7/9 (78.0) | 7/32 (21.9) |
| SLL/CLL | 23/35 (65.0) | 4/31 (12.9) | 8/15 (53.0) | 13/45 (28.9) |
EMZL indicates extranodal marginal zone lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; NMZL, nodal marginal zone lymphoma; SLL/CLL, small lymphocytic lymphoma/chronic lymphocytic leukemia; SMZL, splenic marginal zone lymphoma.